On July 16, Madrigal Pharmaceuticals announced that it had secured a new patent extending that may protect its drug, Rezdiffra, for almost another 20 years. The company announced that the Patent Office had issued a Notice of Allowance for a pending patent application. The press release indicated that the patent will include “claims directed to Rezdiffra’s commercial weight-threshold dosing regimen as prescribed in the FDA-approved label.” Is this patent strong enough to protect the drug from generics until 2044?
Read More
Patent Valuation, Monetization and Investments
Patent Valuation, Monetization and Investments